Amylin Pharmaceuticals, Inc.

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines.

The company was founded in 1987 on the discovery of a hormone, amylin, produced by the same beta cells of the pancreas that make insulin. Since then, Amylin has built a strong foundation on research and development. Amylin's scientists are primarily focused on investigating the potential utility of new peptide hormone candidates. The company has amassed significant research and clinical expertise in metabolic medicine including the areas of diabetes and obesity.

By "Challenging Science," Amylin challenges conventional thinking to create innovative approaches to the discovery, development and commercialization of novel therapies for metabolic diseases. Amylin's approach and dedication are rooted in the belief that they will be "Changing Lives" for millions of people - not only with the drugs currently in late-stage development, but also with their pipeline of future therapies.

Incretin Mimetics Steven V. Edelman, MD TCOYD Newsletter, Vol. 25, 2008 Developments in an Important Class of Treatments for Type 2 Diabetes Diabetes affects multiple hormones in the body; not just insulin. Incretins are hormones released from the intestines after eating that cause insulin secretion and appetite suppression.

TCOYD TV

Amylin: the Partner to Insulin

The Discovery of Incretin Hormones: A Powerful Tool to Fight Type 2 Diabetes and Obesity